1. Home
  2. JRVR vs GLSI Comparison

JRVR vs GLSI Comparison

Compare JRVR & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JRVR

James River Group Holdings Ltd.

HOLD

Current Price

$4.46

Market Cap

288.2M

Sector

Finance

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$21.90

Market Cap

269.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JRVR
GLSI
Founded
2002
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.2M
269.1M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
JRVR
GLSI
Price
$4.46
$21.90
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$7.33
$50.00
AVG Volume (30 Days)
437.1K
130.9K
Earning Date
05-04-2026
05-19-2026
Dividend Yield
0.64%
N/A
EPS Growth
125.82
N/A
EPS
N/A
N/A
Revenue
$687,614,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.76
$7.78
52 Week High
$7.20
$34.10

Technical Indicators

Market Signals
Indicator
JRVR
GLSI
Relative Strength Index (RSI) 57.28 45.66
Support Level $3.79 $21.16
Resistance Level $5.48 $29.89
Average True Range (ATR) 0.17 2.17
MACD 0.08 0.08
Stochastic Oscillator 90.78 61.02

Price Performance

Historical Comparison
JRVR
GLSI

About JRVR James River Group Holdings Ltd.

James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers.

Share on Social Networks: